Role of "cancer stem cells" and cell survival in tumor development and maintenance

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 73, Issue , 2008, Pages 451-459

  Adams, J M ^a   Kelly, P N ^a   Dakic, A ^a   Carotta, S ^a   Nutt, S L ^a   Strasser, A ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER STEM CELL; CELL COUNT; CELL POPULATION; CELL SURVIVAL; CELL TYPE; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; SOLID TUMOR; T CELL LYMPHOMA; TUMOR GROWTH; XENOTRANSPLANTATION; ANIMAL; BIOLOGICAL MODEL; CANCER TRANSPLANTATION; CELL PROLIFERATION; LEUKEMIA; LYMPHOMA; MOUSE; MOUSE MUTANT; NEOPLASM; ONCOGENE MYC; PATHOLOGY; PROTO ONCOGENE; REVIEW; TRANSGENIC MOUSE; XENOGRAFT; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LOSS; CELL SELF-RENEWAL; GENE OVEREXPRESSION; HEMATOPOIETIC SYSTEM TUMOR; LYMPHOMAGENESIS; MOLECULAR CLONING;

MUS;

ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; GENES, BCL-2; GENES, MYC; HUMANS; LEUKEMIA; LYMPHOMA; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASTIC STEM CELLS; TRANSPLANTATION, HETEROLOGOUS;

EID: 68549125521     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2008.73.004     Document Type: Conference Paper

References (63)

1. Adams, J.M. and Cory, S. 2007. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324-1337.
2. Adams, J.M. and Strasser, A. 2008. Is tumour growth sustained by rare cancer stem cells or dominant clones? Cancer Res. 68: 4018-4021.
3. Adams, J.M., Harris, A.W., Pinkert, C.A., Corcoran, L.M., Alexander, W.S., Cory, S., Palmiter, R.D., and Brinster, R.L. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538.
4. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke, M.F. 2003. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. 100: 3983-3988.
5. Arai, K.I., Lee, F., Miyajima, A., Miyatake, S., Arai, N., and Yokota, T. 1990. Cytokines: Coordinators of immune and inflammatory responses. Annu. Rev. Biochem. 59: 783-836.
6. Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Bigner, D.D., and Rich, J.N. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
7. Barker, N., van Es, J.H., Kuipers, J., Kujala, P., van den Born, M., Cozijnsen, M., Haegebarth, A., Korving, J., Begthel, H., Peters, P.J., and Clevers, H. 2007. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007.
8. - glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67: 4010-4015.
9. Bonnet, D. and Dick, J.E. 1997. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3: 730-737.
10. Calabrese, C., Poppleton, H., Kocak, M., Hogg, T.L., Fuller, C., Hamner, B., Oh, E.Y., Gaber, M.W., Finklestein, D., Allen, M., et al. 2007. A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82.
11. Campbell, L.L. and Polyak, K. 2007. Breast tumor heterogeneity: Cancer stem cells or clonal evolution? Cell Cycle 6: 2332-2338.
12. Cho, R.W., Wang, X., Diehn, M., Shedden, K., Chen, G.Y., Sherlock, G., Gurney, A., Lewicki, J., and Clarke, M.F. 2008. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 26: 364-371.
13. Clarke, M.F., Dick, J.E., Dirks, P.B., Eaves, C.J., Jamieson, C.H., Jones, D.L., Visvader, J., Weissman, I.L., and Wahl, G.M. 2006. Cancer stem cells - Perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res. 66: 9339-9344.
14. Cory, S. and Adams, J.M. 2002. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2: 647-656.
15. Deshpande, A.J., Cusan, M., Rawat, V.P., Reuter, H., Krause, A., Pott, C., Quintanilla-Martinez, L., Kakadia, P., Kuchenbauer, F., Ahmed F., et al. 2006. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell 10: 363-374.
16. Fesik, S.W. 2005. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5: 876-885.
17. Furth, J. and Kahn, M.C. 1937. The transmission of leukemia in mice with a single cell. Am. J. Cancer 31: 276-282.
18. Green, D.R. and Evan, G.I. 2002. A matter of life and death. Cancer Cell 1: 19-30.
19. Hanahan, D. and Weinberg, R.A. 2000. The hallmarks of cancer. Cell 100: 57-70.
20. Hansford, L.M., McKee, A.E., Zhang, L., George, R.E., Gerstle, J.T., Thorner, P.S., Smith, K.M., Look, A.T., Yeger, H., Miller, F.D., Irwin, M.S., Thiele, C.J., and Kaplan, D.R. 2007. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res. 67: 11234-11243.
21. Haupt, Y., Harris, A.W., and Adams J.M. 1992. Retroviral infection accelerates T lymphomagenesis in Eμ-N-ras transgenic mice by activating c-myc and N-myc. Oncogene 7: 981-986.
22. Hewitt, H.B., Blake, E.R. and Walder, A.S. 1976. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 33: 241-259.
23. Hill, R.P. and Perris, R. 2007. "Destemming" cancer stem cells. J. Natl. Cancer Inst. 99: 1435-1440.
24. Huntly, B.J., Shigematsu, H., Deguchi, K., Lee, B.H., Mizuno, S., Duclos, N., Rowan, R., Amaral, S., Curley, D., Williams, I.R., Akashi, K., and Gilliland, D.G. 2004. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6: 587-596.
25. Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., Rosenblatt, J., Avigan, D.E., Teruya-Feldstein, J., and Pandolfi, P.P. 2008. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453: 1072-1078.
26. Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F., and Dick, J.E. 2006. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12: 1167-1174.
27. Kelly, P.N., Dakic, A., Adams, J.M., Nutt, S.L., and Strasser, A. 2007a. Tumor growth need not be driven by rare cancer stem cells. Science 317: 337.
28. Kelly, P.N., Puthalakath, H., Adams, J.M., and Strasser, A. 2007b. Endogenous bcl-2 is not required for the development of Eμ-myc-induced B-cell lymphoma. Blood 109: 4907-4913.
29. + cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 22: 1207-1213.
30. Krivtsov, A.V., Twomey, D., Feng, Z., Stubbs, M.C., Wang, Y., Faber, J., Levine, J.E., Wang, J., Hahn, W.C., Gilliland, D.G., Golub, T.R., and Armstrong, S.A. 2006. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442: 818-822.
31. Langdon, W.Y., Harris, A.W., Cory, S., and Adams, J.M. 1986. The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice. Cell 47: 11-18.
32. Letai, A., Sorcinelli, M.D., Beard, C., and Korsmeyer, S.J. 2004. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6: 241-249.
33. Li, Y.-S., Hayakawa, K., and Hardy, R.R. 1993. The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. J. Exp. Med. 178: 951-960.
34. Lin, W.W. and Karin, M. 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 117: 1175-1183.
35. Lindeman, G.J., Adams, J.M., Cory, S., and Harris, A.W. 1994. B-lymphoid to granulocytic switch during hematopoiesis in a transgenic mouse strain. Immunity 1: 517-527.
36. + cancer stem cells in glioblastoma. Mol. Cancer 5: 67.
37. Malanchi, I., Peinado, H., Kassen, D., Hussenet, T., Metzger, D., Chambon, P., Huber, M., Hohl, D., Cano, A., Birchmeier, W., and Huelsken, J. 2008. Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature 452: 650-653.
38. Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., Shipitsin, M., Campbell, L.L., Polyak, K., Brisken, C., Yang, J., and Weinberg, R.A. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
39. McDonnell, T.J., Deane, N., Platt, F.M., Nuñez, G., Jaeger, U., McKearn, J.P. and Korsmeyer, S.J. 1989. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57: 79-88.
40. Metcalf, D., Dakic, A., Mifsud, S., Di Rago, L., Wu, L., and Nutt, S. 2006. Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc. Natl. Acad. Sci. 103: 1486-1491.
41. Morrison, S.J. and Spradling, A.C. 2008. Stem cells and niches: Mechanisms that promote stem cell maintenance throughout life. Cell 132: 598-611.
42. Mullighan, C.G., Miller, C.B., Radtke, I., Phillips, L.A., Dalton, J., Ma, J., White, D., Hughes, T.P., Le Beau, M.M., Pui, C.H., Relling, M.V., Shurtleff, S.A., and Downing, J.R. 2008. BCRABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453: 110-114.
43. Neering, S.J., Bushnell, T., Sozer, S., Ashton, J., Rossi, R.M., Wang, P.Y., Bell, D.R., Heinrich, D., Bottaro, A. and Jordan, C.T. 2007. Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 110: 2578-2585.
44. O'Brien, C.A., Pollett, A., Gallinger, S., and Dick, J.E. 2007. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
45. O'Hare, T., Corbin, A.S., and Druker, B.J. 2006. Targeted CML therapy: Controlling drug resistance, seeking cure. Curr. Opin. Genet. Dev. 16: 92-99.
46. Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., Armstrong, R.C., Augeri, D.J., Belli, B.A., Bruncko, M., Deckwerth, T.L., Dinges, J., Hajduk, P.J., et al. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
47. Pearce, D.J., Taussig, D., Zibara, K., Smith, L.L., Ridler, C.M., Preudhomme, C., Young, B.D., Rohatiner, A.Z., Lister, T.A., and Bonnet D. 2006. AML engraftment in the NOD/SCID assay reflects the outcome of AML: Implications for our understanding of the heterogeneity of AML. Blood 107: 1166-1173.
48. Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., and De Maria, R. 2007. Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
49. Shipitsin, M. and Polyak, K. 2008. The cancer stem cell hypothesis: In search of definitions, markers, and relevance. Lab. Invest. 88: 459-463.
50. - metastatic colon cancer cells initiate tumors. J. Clin. Invest. 118: 2111-2120.
51. Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D., and Dirks, P.B. 2004. Identification of human brain tumour initiating cells. Nature 432: 396-401.
52. Somervaille, T.C. and Cleary, M.L. 2006. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10: 257-268.
53. Strasser, A., Harris, A.W., Bath, M.L., and Cory, S. 1990. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348: 331-333.
54. Strasser, A., Whittingham, S., Vaux, D.L., Bath, M.L., Adams, J.M., Cory, S., and Harris, A.W. 1991. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl. Acad. Sci. 88: 8661-8665.
55. Strasser, A., Elefanty, A.G., Harris, A.W., and Cory, S. 1996. Progenitor tumours from Eμ-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J. 15: 3823-3834.
56. Tse, C., Shoemaker, A.R., Adickes, J., Anderson, M.G., Chen, J., Jin, S., Johnson, E.F., Marsh, K.C., Mitten, M.J., Nimmer, P., et al. 2008. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68: 3421-3428.
57. Veis, D.J., Sorenson, C.M., Shutter, J.R., and Korsmeyer, S.J. 1993. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75: 229-240.
58. Vermeulen, L., Sprick, M.R., Kemper, K., Stassi, G., and Medema, J.P. 2008. Cancer stem cells - Old concepts, new insights. Cell Death Differ. 15: 947-958.
59. Visvader, J. and Lindeman, G.J. 2008. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer (in press).
60. Wang, J.C. and Dick, J.E. 2005. Cancer stem cells: Lessons from leukemia. Trends Cell Biol. 15: 494-501.
61. +, Arf-null lymphoblastic leukemia. Genes Dev. 21: 2283-2287.
62. + cells with cancer stem cell characteristics. Breast Cancer Res. 10: R10.
63. Youle, R.J. and Strasser, A. 2008. The BCL-2 protein family: Opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9: 47-59.